ARCHIVES

Tamoxfin Trial accrues 6,000, Problems with Minority accrual Remain

This article is from The Cancer Letter archive.

Vol. 19 No. 14 | April 2, 1993

Download PDF Visit The Full Archive

Related Articles

Hope for FDA authority over tobacco products dies in Congress.

October 15, 2004

Colorectal Screening Rates Lower In Safety Net System

September 25, 2009

Cooperative Groups Other Investigators To Get Interferon When Available; DCT Recompetitions Okayed

April 4, 1980

Richard Klausner resigned from the Gates Foundation, saying move was unrelated to Congressional investigation of NCI contract to Harvard University during Klausner’s tenure as NCI director.

September 16, 2005

Clinical Trials Approved By NCI CTEP Last Month

March 25, 2011

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014